US INVESTIGATIONS have resulted in huge payouts by two major firms – drugmaker Elan, and the bank Goldman Sachs. The companies were fined a whopping $750 million combined after separate investigations by US officials.
Irish pharmaceutical company Elan will pay a $200 million fine to settle claims arising from a US investigation into how the company marketed its Zonegran medicine. The anti-epileptic drug was sold off by Elan in 2004, and the company had set aside $206 million to cope with costs expected to arise from the probe.
The company is also expected to plead guilty to violating the US Federal Food, Drug and Cosmetic Act, but specific details on the infraction were not released.
US bank Goldman Sachs has agreed to pay $550 million in compensation to settle a fraud action by US regulators against the company. Regulators accused the bank of misleading investors in subprime mortgage products just as the housing market began to collapse.
They said Goldman Sachs had allowed a hedge fund to package subprime mortgages for their clients while simultaneously betting against those packages. The fine is unlikely to have much financial impact on the company, which earned $13.3 billion last year.
It’s a warning we’ve heard many times before and the Irish Blood Transfusion Service (IBTS) puts a decrease in donation in recent months down to a number of factors.
Stephen Cousins, national donor services manager with the IBTS, told us: “If you go back over 10 years, emigration has definitely been a part of it, especially in rural clinics the volume has just fallen.”
He said people travelling to more exotic locations and having less time also play a role.
TheJournal.ie is a full participating member of the Press Council of Ireland and supports
the Office of the Press Ombudsman. This scheme in addition to defending the freedom of the
press, offers readers a quick, fair and free method of dealing with complaints that they may
have in relation to articles that appear on our pages. To contact the Office of the
Press Ombudsman Lo-Call 1890 208 080 or go to
Journal Media does not control and is not responsible for user created content, posts, comments, submissions or preferences. Users are reminded that they are fully responsible for their own created content and their own posts, comments and submissions and fully and effectively warrant and indemnify Journal Media in relation to such content and their ability to make such content, posts, comments and submissions available. Journal Media does not control and is not responsible for the content of external websites.